Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

7.71
-0.1900-2.41%
Post-market: 7.710.00000.00%16:05 EDT
Volume:1.71M
Turnover:13.22M
Market Cap:1.23B
PE:-6.31
High:7.96
Open:7.79
Low:7.62
Close:7.90
Loading ...

Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness

TIPRANKS
·
04 Mar

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com
·
04 Mar

Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions

TIPRANKS
·
04 Mar

Q4 2024 Ocular Therapeutix Inc Earnings Call

Thomson Reuters StreetEvents
·
04 Mar

Ocular Therapeutix Reports 2024 Financial Results and Progress

TIPRANKS
·
04 Mar

Ocular Therapeutix Earnings Call Highlights Progress and Challenges

TIPRANKS
·
04 Mar

Ocular Therapeutix: Strategic Amendments and Financial Strength Justify Buy Rating

TIPRANKS
·
04 Mar

BUZZ-Ocular slides on Q4 revenue miss

Reuters
·
04 Mar

Ocular Therapeutix Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Mar

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
03 Mar

Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
03 Mar

Ocular Therapeutix: Q4 Earnings Snapshot

Associated Press Finance
·
03 Mar

Earnings Flash (OCUL) Ocular Therapeutix Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.25 Loss

MT Newswires Live
·
03 Mar

Ocular Therapeutix Q4 2024 GAAP EPS $(0.29) Misses $(0.24) Estimate, Sales $17.08M Miss $17.20M Estimate

Benzinga
·
03 Mar

BRIEF-Ocular Therapeutix Q4 EPS USD -0.29

Reuters
·
03 Mar

Ocular Therapeutix Q4 Product Revenue USD 17.02 Million

THOMSON REUTERS
·
03 Mar

Ocular Therapeutix Inc: Currently Does Not Intend to Raise Additional Capital This Year

THOMSON REUTERS
·
03 Mar

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

GlobeNewswire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Zacks
·
25 Feb